Gene Therapy Company Emendo Biotherapeutics Raises $61 Million
Emendo uses protein engineering to treat certain genetic disorders and diseases
11:3716.01.20
New York-based gene therapy company Emendo Biotherapeutics Inc. has raised a $61 million series B funding round, the company announced Wednesday. The round was led by Tokyo-listed pharmaceutical company AnGes Inc.
Protein engineering (illustration). Photo: Pixabay
Founded in 2015 by alumni of Israel's Weizmann Institute of Science Lior Izhar, David Baram, and Rachel Diamant, Emendo utilizes protein engineering for precision gene editing, altering single alleles to treat certain genetic disorders and diseases. The company has raised $73 million to date, according to Pitchbook data.
Protein engineering (illustration). Photo: Pixabay
